Dislipidemia
Published on May 17, 2026
Risk Factors
Smoking, hypertension, diabetes mellitus, obesity (BMI ≥25 kg/m2 for Asian), family history of premature CHD (male <55, female <65), age (male ≥45, female ≥55), chronic kidney disease, chronic inflammatory conditions, metabolic syndrome
Etiology
Primary (genetic): familial hypercholesterolemia, familial combined dyslipidemia, primary hypertriglyceridemia. Secondary: hypothyroidism, nephrotic syndrome, DM type 2, chronic alcohol use, medications (thiazides, beta-blockers, corticosteroids, protease inhibitors, oral contraceptives)
Presentation
Usually asymptomatic. Discovered incidentally on routine screening. Symptomatic presentations are complications: chest pain (CHD), focal neurological deficit (stroke), severe epigastric pain (pancreatitis from TG ≥500 mg/dL)
Classic Exam
Xanthoma (tendon: Achilles, elbow, knee), xanthelasma (eyelid), arcus corneae (in young patients suggests familial hypercholesterolemia), lipemia retinalis (cream-colored retinal vessels in severe hypertriglyceridemia), hepatosplenomegaly
Diagnostics
Fasting lipid profile: Total cholesterol ≥240 mg/dL (high), LDL-C ≥190 mg/dL (very high), HDL-C <40 mg/dL (low), TG ≥200 mg/dL (high). Friedewald formula: (invalid if TG >400 mg/dL)
Management
Lifestyle modification (diet, exercise, smoking cessation) for all patients. Statins are first-line pharmacotherapy. Ezetimibe and PCSK9 inhibitors as add-on for high/very-high risk patients not reaching target. Fibrates for TG ≥500 mg/dL to prevent pancreatitis
Keywords
"Xanthoma on Achilles tendon," "arcus corneae in young adult," "milky plasma," "fasting lipid profile," "LDL target," "Framingham risk score," "statin intensity," "10-year cardiovascular risk"
01Pathophysiology
Dyslipidemia is a disorder of lipid metabolism characterized by elevation or reduction of one or more plasma lipid fractions. The principal abnormalities are elevated total cholesterol, elevated LDL-C, elevated triglycerides, and/or decreased HDL-C.
To understand why LDL-C is the primary therapeutic target, you must understand lipoprotein metabolism. The liver releases nascent VLDL containing apo B-100, apo E, apo C1, cholesteryl esters, and triglycerides into circulation. HDL donates apo C-II to nascent VLDL, making it mature. Mature VLDL interacts with lipoprotein lipase (LPL) on capillary endothelium of adipose tissue, cardiac muscle, and skeletal muscle, where triglycerides are extracted for energy use or storage.
VLDL then exchanges triglycerides for cholesteryl esters with HDL via cholesteryl ester transfer protein (CETP). This process reduces VLDL triglyceride content, converting it into IDL. Approximately half of IDL undergoes hepatic endocytosis (recognized by apo B-100 and apo E). The remaining IDL, now enriched in cholesterol relative to triglycerides and lacking apo E, transforms into LDL.
LDL particles contain apo B-100, the ligand recognized by hepatic LDL receptors (LDLR). When circulating LDL is excessive or LDLR expression is reduced (as in familial hypercholesterolemia), LDL accumulates in the plasma and undergoes oxidative modification. Oxidized LDL penetrates the arterial intima, is engulfed by macrophages via scavenger receptors, and forms foam cells, which is the earliest hallmark of atherosclerotic plaque formation.
HDL, carrying apo A-I and apo A-II, mediates reverse cholesterol transport, removing cholesterol from peripheral tissues back to the liver. This is why low HDL-C is considered atherogenic and why HDL is often called the "protective" lipoprotein.
The atherosclerotic plaque is a lipid-rich, inflammatory lesion covered by a fibrous cap. When the cap erodes, ulcerates, or ruptures, the thrombogenic core is exposed, triggering acute thrombosis, which is the direct mechanism behind acute coronary syndrome and ischemic stroke.
Statins work by competitively inhibiting HMG-CoA reductase, the rate-limiting enzyme in hepatic cholesterol synthesis. Reduced intracellular cholesterol upregulates LDLR expression on hepatocyte surfaces, increasing LDL clearance from blood. Beyond lipid lowering, statins exert pleiotropic effects: improving endothelial function, stabilizing plaque, reducing oxidative stress, and decreasing vascular inflammation.
02Classification and Clinical Manifestation
Classification of Plasma Lipid Levels
Total Cholesterol
Category
Desirable
Value (mg/dL)
<200
Total Cholesterol
Category
Borderline high
Value (mg/dL)
200-239
Total Cholesterol
Category
High
Value (mg/dL)
≥240
LDL-C
Category
Optimal
Value (mg/dL)
<100
LDL-C
Category
Near optimal
Value (mg/dL)
100-129
LDL-C
Category
Borderline high
Value (mg/dL)
130-159
LDL-C
Category
High
Value (mg/dL)
160-189
LDL-C
Category
Very high
Value (mg/dL)
≥190
HDL-C
Category
Low
Value (mg/dL)
<40
HDL-C
Category
High (protective)
Value (mg/dL)
≥60
Triglycerides
Category
Normal
Value (mg/dL)
<150
Triglycerides
Category
Borderline high
Value (mg/dL)
150-199
Triglycerides
Category
High
Value (mg/dL)
200-499
Triglycerides
Category
Very high
Value (mg/dL)
≥500
Lipid Fraction | Category | Value (mg/dL) |
|---|---|---|
Total Cholesterol | Desirable | <200 |
Borderline high | 200-239 | |
High | ≥240 | |
LDL-C | Optimal | <100 |
Near optimal | 100-129 | |
Borderline high | 130-159 | |
High | 160-189 | |
Very high | ≥190 | |
HDL-C | Low | <40 |
High (protective) | ≥60 | |
Triglycerides | Normal | <150 |
Borderline high | 150-199 | |
High | 200-499 | |
Very high | ≥500 |
Classification by Etiology
Primary (Genetic)
Description
Polygenic hypercholesterolemia, familial combined dyslipidemia, familial hypercholesterolemia, remnant dyslipidemia, primary hypertriglyceridemia
Key Features
Suspect when severe dyslipidemia is found in a young patient with xanthoma, xanthelasma, or arcus corneae, especially with a family history of premature CHD
Secondary
Description
Dyslipidemia caused by an underlying condition
Key Features
Treat the primary disease first. Exceptions: DM patients always require statin therapy because DM is considered a CHD risk equivalent
Type | Description | Key Features |
|---|---|---|
Primary (Genetic) | Polygenic hypercholesterolemia, familial combined dyslipidemia, familial hypercholesterolemia, remnant dyslipidemia, primary hypertriglyceridemia | Suspect when severe dyslipidemia is found in a young patient with xanthoma, xanthelasma, or arcus corneae, especially with a family history of premature CHD |
Secondary | Dyslipidemia caused by an underlying condition | Treat the primary disease first. Exceptions: DM patients always require statin therapy because DM is considered a CHD risk equivalent |
Secondary Causes of Dyslipidemia
Lipid Abnormality | Causes |
|---|---|
Elevated Total Cholesterol and LDL-C | Hypothyroidism, nephrotic syndrome, cholestatic liver disease, progestin/anabolic steroid therapy, protease inhibitor therapy (HIV), dysgammaglobulinemia |
Elevated Triglycerides and VLDL | DM type 2, obesity, chronic kidney disease, high alcohol intake, hypothyroidism, thiazides, beta-blockers, corticosteroids, oral contraceptives/estrogen, pregnancy, protease inhibitors (HIV) |
Clinical Manifestations
Feature | Clinical Significance |
|---|---|
Xanthoma (tendon) | Achilles, elbow, knee. Strongly associated with familial hypercholesterolemia (very high LDL-C) |
Xanthelasma | Yellowish plaques on eyelids. Can occur in normal lipid levels but raises suspicion for dyslipidemia |
Arcus corneae | Lipid deposition at corneal periphery. In patients <45 years old, highly suggestive of familial hypercholesterolemia |
Lipemia retinalis | Cream-colored retinal vessels. Indicates very high TG (≥500 mg/dL) |
Eruptive xanthomas | Yellowish papules over trunk and extremities, associated with very high TG |
Acute pancreatitis | Major complication of TG ≥500 mg/dL. The primary goal of treating severe hypertriglyceridemia is pancreatitis prevention, not cardiovascular prevention |
03Diagnostic Workup
Fasting lipid profile (Total-C, LDL-C, HDL-C, TG)
Role
Best initial test (Level I/C recommendation)
Key Points
12-hour fast required for accurate TG and calculated LDL. Non-fasting Total-C and HDL-C are acceptable for initial screening
Friedewald formula
Role
Calculates LDL-C
Key Points
. Invalid when TG >400 mg/dL
Direct LDL-C measurement
Role
Confirmatory when Friedewald is invalid
Key Points
Order when non-fasting TG ≥400 mg/dL
Non-HDL Cholesterol
Role
Secondary target (Level IIa/B)
Key Points
. Useful when TG 200-499 mg/dL, in DM, metabolic syndrome, CKD, or established CVD. Target = LDL target + 30 mg/dL
Apo B
Role
Alternative marker (Level IIa/C)
Key Points
Reflects total atherogenic particle concentration. Equivalent to non-HDL-C. More accurate with lower variability, especially with high TG
Lipoprotein(a)
Role
Risk enhancer (Level IIa/C)
Key Points
Consider in patients with family history of premature CVD or borderline risk between high and moderate
Framingham Risk Score
Role
10-year CVD risk calculator
Key Points
Uses age, sex, total cholesterol, HDL-C, systolic BP, treatment status, diabetes, smoking status. Classifies into low (<10%), intermediate (10-19%), high (≥20%)
Coronary Artery Calcium (CAC) Score
Role
Risk reclassification tool
Key Points
CAC = 0 indicates low risk (may defer statin). CAC ≥100 indicates >7.5% 10-year risk (supports statin initiation). Most useful in intermediate-risk patients where the decision to start statin is uncertain
Test | Role | Key Points |
|---|---|---|
Fasting lipid profile (Total-C, LDL-C, HDL-C, TG) | Best initial test (Level I/C recommendation) | 12-hour fast required for accurate TG and calculated LDL. Non-fasting Total-C and HDL-C are acceptable for initial screening |
Friedewald formula | Calculates LDL-C | . Invalid when TG >400 mg/dL |
Direct LDL-C measurement | Confirmatory when Friedewald is invalid | Order when non-fasting TG ≥400 mg/dL |
Non-HDL Cholesterol | Secondary target (Level IIa/B) | . Useful when TG 200-499 mg/dL, in DM, metabolic syndrome, CKD, or established CVD. Target = LDL target + 30 mg/dL |
Apo B | Alternative marker (Level IIa/C) | Reflects total atherogenic particle concentration. Equivalent to non-HDL-C. More accurate with lower variability, especially with high TG |
Lipoprotein(a) | Risk enhancer (Level IIa/C) | Consider in patients with family history of premature CVD or borderline risk between high and moderate |
Framingham Risk Score | 10-year CVD risk calculator | Uses age, sex, total cholesterol, HDL-C, systolic BP, treatment status, diabetes, smoking status. Classifies into low (<10%), intermediate (10-19%), high (≥20%) |
Coronary Artery Calcium (CAC) Score | Risk reclassification tool | CAC = 0 indicates low risk (may defer statin). CAC ≥100 indicates >7.5% 10-year risk (supports statin initiation). Most useful in intermediate-risk patients where the decision to start statin is uncertain |
The diagnostic approach begins with identifying who should be screened. Screening is indicated for all patients with cardiovascular disease manifestations or risk factors including: active smokers, diabetics, hypertensive patients, family history of premature CHD or hyperlipidemia, CKD, chronic inflammatory disease, central obesity (waist circumference >90 cm male / >80 cm female), obesity (BMI ≥25 for Asians), erectile dysfunction, evidence of atherosclerosis, males ≥40 years or postmenopausal females.
The fasting lipid profile (Total-C, LDL-C, HDL-C, TG) is the initial panel ordered in all patients. A 12-hour fast is required primarily because triglyceride levels are affected by recent food intake, and the Friedewald formula uses TG to calculate LDL-C.
A critical exam trap involves the Friedewald formula limitation: it cannot be used when TG exceeds 400 mg/dL, in Frederickson type III dyslipidemia, or in the presence of apo E2/E2 phenotype. When this formula is invalid, a direct LDL-C measurement must be ordered.
After the lipid profile is obtained, the next step is to calculate the patient's 10-year cardiovascular risk using tools such as the Framingham Risk Score, Pooled Cohort Equations, or SCORE. This risk stratification determines the patient's risk category and drives all subsequent treatment decisions, including LDL-C targets and statin intensity.
04Management and Treatment
Non-Pharmacological Therapy
Intervention | Details |
|---|---|
Physical activity | ≥30 min moderate intensity, 4-6 times/week, ≥200 kcal/day expenditure. Brisk walking, cycling, swimming. Resistance training ≥2 days/week |
Medical nutrition therapy | ≥5 portions/day fruits and vegetables, ≥6 portions/day whole grains, limit saturated fat, trans fat, and dietary cholesterol. Plant stanols/sterols 2 g/day, soluble fiber 10-25 g/day |
Smoking cessation | Cessation for ≥30 days significantly increases HDL-C |
Weight reduction | Target BMI <25 kg/m2 (Asian criteria) |
Reduce alcohol intake | Limit or eliminate alcohol consumption |
Pharmacological Therapy Summary
Statin
LDL-C Effect
↓ 18-55%
TG Effect
↓ 7-30%
HDL-C Effect
↑ 5-15%
Key Side Effects
Myopathy, elevated liver enzymes
Contraindications
Absolute: acute/chronic liver disease. Relative: drug interactions
Ezetimibe
LDL-C Effect
↓ 10-18%
TG Effect
Minimal
HDL-C Effect
Minimal
Key Side Effects
Generally well tolerated
Contraindications
Liver disease, elevated liver enzymes
PCSK9 Inhibitor
LDL-C Effect
↓ 48-71%
TG Effect
Minimal
HDL-C Effect
Minimal
Key Side Effects
Injection site reaction, pharyngitis, myalgia
Contraindications
No long-term safety data beyond 3 years
Fibrate
LDL-C Effect
↓ 5-20%
TG Effect
↓ 20-50%
HDL-C Effect
↑ 10-20%
Key Side Effects
Dyspepsia, gallstones, myopathy
Contraindications
Severe renal or hepatic disease
Bile Acid Sequestrant
LDL-C Effect
↓ 15-30%
TG Effect
No change / may increase
HDL-C Effect
↑ 3-5%
Key Side Effects
GI disturbance, constipation, decreased absorption of other drugs
Contraindications
Dysbetalipoproteinemia, TG >400 mg/dL
Nicotinic Acid (Niacin)
LDL-C Effect
↓ 5-25%
TG Effect
↓ 20-50%
HDL-C Effect
↑ 15-35%
Key Side Effects
Flushing, hyperglycemia, hyperuricemia, hepatotoxicity
Contraindications
Chronic liver disease, severe gout
Omega-3 Fatty Acids
LDL-C Effect
Minimal (may ↑ LDL)
TG Effect
↓ 27-45%
HDL-C Effect
Minimal
Key Side Effects
Prolonged bleeding time, GI disturbance
Contraindications
Anticoagulant therapy, hepatic dysfunction
Drug Class | LDL-C Effect | TG Effect | HDL-C Effect | Key Side Effects | Contraindications |
|---|---|---|---|---|---|
Statin | ↓ 18-55% | ↓ 7-30% | ↑ 5-15% | Myopathy, elevated liver enzymes | Absolute: acute/chronic liver disease. Relative: drug interactions |
Ezetimibe | ↓ 10-18% | Minimal | Minimal | Generally well tolerated | Liver disease, elevated liver enzymes |
PCSK9 Inhibitor | ↓ 48-71% | Minimal | Minimal | Injection site reaction, pharyngitis, myalgia | No long-term safety data beyond 3 years |
Fibrate | ↓ 5-20% | ↓ 20-50% | ↑ 10-20% | Dyspepsia, gallstones, myopathy | Severe renal or hepatic disease |
Bile Acid Sequestrant | ↓ 15-30% | No change / may increase | ↑ 3-5% | GI disturbance, constipation, decreased absorption of other drugs | Dysbetalipoproteinemia, TG >400 mg/dL |
Nicotinic Acid (Niacin) | ↓ 5-25% | ↓ 20-50% | ↑ 15-35% | Flushing, hyperglycemia, hyperuricemia, hepatotoxicity | Chronic liver disease, severe gout |
Omega-3 Fatty Acids | Minimal (may ↑ LDL) | ↓ 27-45% | Minimal | Prolonged bleeding time, GI disturbance | Anticoagulant therapy, hepatic dysfunction |
Statin Classification by Intensity
High
Expected LDL-C Reduction
≥50%
Examples
Atorvastatin 40-80 mg, Rosuvastatin 20-40 mg
Moderate
Expected LDL-C Reduction
30% to <50%
Examples
Atorvastatin 10-20 mg, Rosuvastatin 5-10 mg, Simvastatin 20-40 mg, Pravastatin 40-80 mg, Pitavastatin 1-4 mg
Low
Expected LDL-C Reduction
<30%
Examples
Simvastatin 10 mg, Pravastatin 10-20 mg, Lovastatin 20 mg, Fluvastatin 20-40 mg
Intensity | Expected LDL-C Reduction | Examples |
|---|---|---|
High | ≥50% | Atorvastatin 40-80 mg, Rosuvastatin 20-40 mg |
Moderate | 30% to <50% | Atorvastatin 10-20 mg, Rosuvastatin 5-10 mg, Simvastatin 20-40 mg, Pravastatin 40-80 mg, Pitavastatin 1-4 mg |
Low | <30% | Simvastatin 10 mg, Pravastatin 10-20 mg, Lovastatin 20 mg, Fluvastatin 20-40 mg |
Risk Categories and LDL-C Targets (PERKENI 2021 / AACE 2017)
Extreme
Criteria
Progressive CVD despite LDL <70, clinical CVD + DM or CKD 3-4 or familial hypercholesterolemia, premature CVD (M<55, F<65)
LDL-C Target
<55 mg/dL
Non-HDL-C Target
<80 mg/dL
Apo B Target
<70 mg/dL
Very High
Criteria
Clinical CAD/carotid disease/PAD, 10-yr risk >20%, DM or CKD 3-4 + ≥1 other risk factor, familial hypercholesterolemia
LDL-C Target
<70 mg/dL
Non-HDL-C Target
<100 mg/dL
Apo B Target
<80 mg/dL
High
Criteria
≥2 risk factors + 10-yr risk 10-20%, DM or CKD 3-4 without other risk factors
LDL-C Target
<100 mg/dL
Non-HDL-C Target
<130 mg/dL
Apo B Target
<90 mg/dL
Moderate
Criteria
≤2 risk factors + 10-yr risk <10%
LDL-C Target
<100 mg/dL
Non-HDL-C Target
<130 mg/dL
Apo B Target
<90 mg/dL
Low
Criteria
0 risk factors
LDL-C Target
<130 mg/dL
Non-HDL-C Target
<160 mg/dL
Apo B Target
Not required
Risk Category | Criteria | LDL-C Target | Non-HDL-C Target | Apo B Target |
|---|---|---|---|---|
Extreme | Progressive CVD despite LDL <70, clinical CVD + DM or CKD 3-4 or familial hypercholesterolemia, premature CVD (M<55, F<65) | <55 mg/dL | <80 mg/dL | <70 mg/dL |
Very High | Clinical CAD/carotid disease/PAD, 10-yr risk >20%, DM or CKD 3-4 + ≥1 other risk factor, familial hypercholesterolemia | <70 mg/dL | <100 mg/dL | <80 mg/dL |
High | ≥2 risk factors + 10-yr risk 10-20%, DM or CKD 3-4 without other risk factors | <100 mg/dL | <130 mg/dL | <90 mg/dL |
Moderate | ≤2 risk factors + 10-yr risk <10% | <100 mg/dL | <130 mg/dL | <90 mg/dL |
Low | 0 risk factors | <130 mg/dL | <160 mg/dL | Not required |
Treatment Algorithms: Alur 1 (ATP III) vs Alur 2 (ACC/AHA 2018)
These are the two clinical pathways recommended by PERKENI 2021 for managing dyslipidemia in Indonesia. Alur 1 adapts the NCEP-ATP III framework and remains relevant for resource-limited settings across the Indonesian archipelago. Alur 2 follows the ACC/AHA 2018 guideline and is considered an alternative for urban populations and patients with adequate access to advanced diagnostic and therapeutic modalities.
ALUR 1: NCEP-ATP III Pathway
This algorithm is target-driven: it assigns a numerical LDL-C goal based on the patient's risk category.
Very High Risk
Criteria
CHD + multiple risk factors (especially diabetes) and/or inadequate risk factor control (e.g., still smoking) and/or metabolic syndrome features
LDL-C Target
<70 mg/dL
Start Statin When
Immediately, regardless of LDL-C level
High Risk
Criteria
CHD or CHD risk equivalent (carotid artery disease, PAD, abdominal aortic aneurysm) without additional high-risk multipliers
LDL-C Target
<100 mg/dL
Start Statin When
LDL-C ≥130 mg/dL (optional at 100-129 mg/dL)
Moderately High Risk
Criteria
No CHD/equivalent, >2 major risk factors, Framingham 10-year risk 10-20%
LDL-C Target
<130 mg/dL
Start Statin When
LDL-C ≥130 mg/dL
Moderate Risk
Criteria
No CHD/equivalent, 2 major risk factors, Framingham 10-year risk <10%
LDL-C Target
<130 mg/dL
Start Statin When
LDL-C ≥160 mg/dL
Low Risk
Criteria
No CHD/equivalent, 0-1 major risk factor
LDL-C Target
<160 mg/dL
Start Statin When
LDL-C ≥190 mg/dL
Risk Category | Criteria | LDL-C Target | Start Statin When |
|---|---|---|---|
Very High Risk | CHD + multiple risk factors (especially diabetes) and/or inadequate risk factor control (e.g., still smoking) and/or metabolic syndrome features | <70 mg/dL | Immediately, regardless of LDL-C level |
High Risk | CHD or CHD risk equivalent (carotid artery disease, PAD, abdominal aortic aneurysm) without additional high-risk multipliers | <100 mg/dL | LDL-C ≥130 mg/dL (optional at 100-129 mg/dL) |
Moderately High Risk | No CHD/equivalent, >2 major risk factors, Framingham 10-year risk 10-20% | <130 mg/dL | LDL-C ≥130 mg/dL |
Moderate Risk | No CHD/equivalent, 2 major risk factors, Framingham 10-year risk <10% | <130 mg/dL | LDL-C ≥160 mg/dL |
Low Risk | No CHD/equivalent, 0-1 major risk factor | <160 mg/dL | LDL-C ≥190 mg/dL |
CHD and CHD Risk Equivalents
Category | Conditions |
|---|---|
CHD (Coronary Heart Disease) | Acute coronary syndrome, history of myocardial infarction, stable/unstable angina, coronary revascularization (PCI or CABG) |
CHD Risk Equivalents | Symptomatic carotid artery disease, peripheral arterial disease (PAD), abdominal aortic aneurysm, diabetes mellitus |
Table 2: Major Risk Factors (Other Than LDL-C)
Risk Factor | Definition |
|---|---|
Smoking | Active smoker |
Hypertension | BP ≥140/90 mmHg or currently on antihypertensive therapy |
Low HDL-C | HDL-C <40 mg/dL |
Family history of premature CHD | First-degree relative with CHD: male <55 years or female <65 years |
Age | Male ≥45 years or female ≥55 years |
ALUR 2: ACC/AHA 2018 Pathway
This algorithm is intensity-driven with a hybrid approach: it groups patients into four clinical categories, prescribes statin intensity accordingly, and introduces LDL-C thresholds (≥70 mg/dL) as triggers for adding non-statin agents in very high-risk patients. This represents a departure from ACC/AHA 2013, which had no numerical LDL-C targets at all.
Group 1: Clinical ASCVD (Secondary Prevention)
This includes patients with a history of ACS, MI, stable/unstable angina, coronary revascularization, stroke, TIA, or PAD (including aortic aneurysm).
For patients ≤75 years: start high-intensity statin aiming for ≥50% LDL-C reduction. If high-intensity statin is contraindicated or not tolerated, use moderate-intensity statin targeting 30-49% reduction.
Within this group, further stratify into very high ASCVD risk if the patient has: history of multiple major ASCVD events, or one major ASCVD event plus multiple high-risk conditions. For these very high-risk patients, if LDL-C remains ≥70 mg/dL on maximally tolerated statin, add ezetimibe. If LDL-C is still ≥70 mg/dL or non-HDL-C ≥100 mg/dL after statin + ezetimibe, consider adding a PCSK9 inhibitor after discussing the benefits, risks, and costs with the patient.
For patients >75 years: initiate or continue moderate-to-high intensity statin after evaluating benefits versus risks of side effects and drug interactions. If LDL-C ≥70 mg/dL on maximally tolerated statin, add ezetimibe.
For patients with heart failure and reduced ejection fraction due to ischemic heart disease, with a life expectancy of 3-5 years: consider moderate-intensity statin.
Group 2: Severe Hypercholesterolemia (LDL-C ≥190 mg/dL)
For patients aged 20-75 years: start maximally tolerated high-intensity statin. If LDL-C reduction is <50% or LDL-C remains ≥100 mg/dL, add ezetimibe. If still inadequate, add bile acid sequestrant (provided TG ≤300 mg/dL).
Consider PCSK9 inhibitor in two scenarios: (a) Heterozygous familial hypercholesterolemia, age 30-75, LDL-C remains ≥100 mg/dL despite maximally tolerated statin + ezetimibe. (b) Age 40-75, baseline LDL-C ≥220 mg/dL, and LDL-C remains ≥130 mg/dL despite maximally tolerated statin + ezetimibe.
Group 3: Diabetes Mellitus (Age 40-75 years)
Start moderate-intensity statin regardless of baseline lipid levels, without needing a 10-year risk calculation. If the patient has multiple risk factors, upgrade to high-intensity statin aiming for ≥50% LDL-C reduction. If 10-year ASCVD risk is ≥20%, add ezetimibe when LDL-C target is not met on maximally tolerated statin.
For DM patients aged 20-39: statin is not routinely recommended unless risk enhancers are present (DM duration ≥10 years for type 2 or ≥20 years for type 1, albuminuria ≥30 mcg/mg, GFR <60, retinopathy, neuropathy, ABI <0.9).
For DM patients with established CVD: target LDL-C <70 mg/dL. If not achieved with high-intensity statin, add ezetimibe or consider PCSK9 inhibitor.
For DM patients aged >75: continue statin if already on therapy.
Group 4: Primary Prevention (No ASCVD, No DM, LDL-C 70-189 mg/dL)
For patients aged 40-75: calculate 10-year ASCVD risk.
≥20%
Category
High risk
Statin Recommendation
High-intensity statin
7.5% to <20%
Category
Intermediate risk
Statin Recommendation
Moderate-intensity statin. Evaluate risk enhancers. Consider CAC scoring if decision remains uncertain
5% to <7.5%
Category
Borderline risk
Statin Recommendation
Evaluate risk enhancers. Consider moderate-intensity statin if risk enhancers are present
<5%
Category
Low risk
Statin Recommendation
Lifestyle modification. Periodic risk reassessment
10-Year Risk | Category | Statin Recommendation |
|---|---|---|
≥20% | High risk | High-intensity statin |
7.5% to <20% | Intermediate risk | Moderate-intensity statin. Evaluate risk enhancers. Consider CAC scoring if decision remains uncertain |
5% to <7.5% | Borderline risk | Evaluate risk enhancers. Consider moderate-intensity statin if risk enhancers are present |
<5% | Low risk | Lifestyle modification. Periodic risk reassessment |
The risk enhancers that favor statin initiation include: family history of premature ASCVD, primary hypercholesterolemia (LDL-C 160-189 mg/dL), metabolic syndrome, CKD, chronic inflammatory conditions (RA, psoriasis, HIV/AIDS), premature menopause (<40 years), preeclampsia history, persistent hypertriglyceridemia (≥175 mg/dL), hs-CRP ≥2 mg/dL, elevated Lp(a), apo B ≥130 mg/dL, and ABI <0.9.
The CAC score is used when the risk calculation places the patient in an ambiguous zone: if CAC = 0, statin can reasonably be deferred; if CAC ≥100, the 10-year risk exceeds 7.5% and statin initiation is appropriate.
For patients aged 20-39: prioritize lifestyle modification. Pharmacotherapy is selective, only for those with LDL-C ≥160 mg/dL (moderately high) or ≥190 mg/dL (very high).
For patients aged >75: evidence from RCTs is limited. The decision to initiate or continue statin is made through shared decision-making between patient and clinician.
Monitoring
Lipid profile
Timing
Before therapy, every 4-12 weeks until target is reached, then annually
Action Threshold
Adjust statin dose or add agents based on LDL-C target achievement
SGPT (ALT)
Timing
Before therapy, then once at weeks 8-12
Action Threshold
If <3x ULN: continue therapy, recheck at weeks 4-6. If >3x ULN: stop/reduce dose, recheck at weeks 4-6
CK
Timing
Before therapy only. Repeat only if myalgia is reported
Action Threshold
Do not start if CK >4x ULN. If CK >10x ULN: stop statin, check renal function, recheck CK every 2 weeks
HbA1c
Timing
Regularly in patients at risk for diabetes
Action Threshold
Long-term statin therapy increases diabetes risk, especially in patients with obesity, metabolic syndrome, elderly, or insulin resistance
Parameter | Timing | Action Threshold |
|---|---|---|
Lipid profile | Before therapy, every 4-12 weeks until target is reached, then annually | Adjust statin dose or add agents based on LDL-C target achievement |
SGPT (ALT) | Before therapy, then once at weeks 8-12 | If <3x ULN: continue therapy, recheck at weeks 4-6. If >3x ULN: stop/reduce dose, recheck at weeks 4-6 |
CK | Before therapy only. Repeat only if myalgia is reported | Do not start if CK >4x ULN. If CK >10x ULN: stop statin, check renal function, recheck CK every 2 weeks |
HbA1c | Regularly in patients at risk for diabetes | Long-term statin therapy increases diabetes risk, especially in patients with obesity, metabolic syndrome, elderly, or insulin resistance |
05Differential Diagnosis and Distractors
Hypothyroidism
Why It Is Similar
Causes elevated total cholesterol and LDL-C, may present with fatigue and weight gain
Key Discriminator
Check TSH. Hypothyroidism is a secondary cause; treating it with levothyroxine corrects the dyslipidemia. Look for cold intolerance, constipation, delayed DTR relaxation phase
Nephrotic syndrome
Why It Is Similar
Causes severe hypercholesterolemia (elevated total-C, LDL-C, and TG)
Key Discriminator
Look for proteinuria >3.5 g/day, hypoalbuminemia, peripheral edema. The dyslipidemia is secondary to increased hepatic lipoprotein synthesis driven by hypoalbuminemia
Metabolic syndrome
Why It Is Similar
Overlapping features: central obesity, hypertriglyceridemia, low HDL-C, hypertension, hyperglycemia
Key Discriminator
Metabolic syndrome is a cluster of risk factors, not a single lipid diagnosis. Requires ≥3 of 5 criteria. Dyslipidemia is one component, not the entire picture
Familial hypercholesterolemia (FH)
Why It Is Similar
Very high LDL-C (often ≥190 mg/dL), premature CVD
Key Discriminator
Tendon xanthoma (especially Achilles), arcus corneae at age <45, family history of premature CHD in first-degree relatives. Homozygous FH presents in childhood with LDL-C >500 mg/dL
Pancreatitis from hypertriglyceridemia
Why It Is Similar
Presents with severe epigastric pain, may be confused with biliary or peptic disease
Key Discriminator
TG ≥500 mg/dL with lipemia retinalis or milky-appearing plasma. The pancreatitis is a direct consequence of severely elevated TG, and the primary treatment goal is lowering TG to prevent recurrence, not lowering LDL-C
Cholestatic liver disease (e.g., primary biliary cirrhosis)
Why It Is Similar
Markedly elevated total cholesterol and LDL-C
Key Discriminator
Elevated alkaline phosphatase and GGT, jaundice, pruritus, positive antimitochondrial antibodies (AMA). Dyslipidemia resolves with treatment of underlying cholestasis
Diagnosis | Why It Is Similar | Key Discriminator |
|---|---|---|
Hypothyroidism | Causes elevated total cholesterol and LDL-C, may present with fatigue and weight gain | Check TSH. Hypothyroidism is a secondary cause; treating it with levothyroxine corrects the dyslipidemia. Look for cold intolerance, constipation, delayed DTR relaxation phase |
Nephrotic syndrome | Causes severe hypercholesterolemia (elevated total-C, LDL-C, and TG) | Look for proteinuria >3.5 g/day, hypoalbuminemia, peripheral edema. The dyslipidemia is secondary to increased hepatic lipoprotein synthesis driven by hypoalbuminemia |
Metabolic syndrome | Overlapping features: central obesity, hypertriglyceridemia, low HDL-C, hypertension, hyperglycemia | Metabolic syndrome is a cluster of risk factors, not a single lipid diagnosis. Requires ≥3 of 5 criteria. Dyslipidemia is one component, not the entire picture |
Familial hypercholesterolemia (FH) | Very high LDL-C (often ≥190 mg/dL), premature CVD | Tendon xanthoma (especially Achilles), arcus corneae at age <45, family history of premature CHD in first-degree relatives. Homozygous FH presents in childhood with LDL-C >500 mg/dL |
Pancreatitis from hypertriglyceridemia | Presents with severe epigastric pain, may be confused with biliary or peptic disease | TG ≥500 mg/dL with lipemia retinalis or milky-appearing plasma. The pancreatitis is a direct consequence of severely elevated TG, and the primary treatment goal is lowering TG to prevent recurrence, not lowering LDL-C |
Cholestatic liver disease (e.g., primary biliary cirrhosis) | Markedly elevated total cholesterol and LDL-C | Elevated alkaline phosphatase and GGT, jaundice, pruritus, positive antimitochondrial antibodies (AMA). Dyslipidemia resolves with treatment of underlying cholestasis |
06Traps and High-Yield Pearls
The most common way students lose points on dyslipidemia questions is by failing to connect the patient's risk category to the correct LDL-C target and statin intensity. Test-writers frequently construct vignettes where the lipid values alone appear borderline, but the presence of diabetes, CKD, or established CVD dramatically changes the management. For instance, a patient with LDL-C of 110 mg/dL would not need pharmacotherapy in the low-risk category (target <160), but the same value in a patient with diabetes and established CHD (extreme risk, target <55) demands aggressive statin therapy and potentially add-on ezetimibe or a PCSK9 inhibitor.
Another classic trap involves the Friedewald formula. Exam vignettes will deliberately present a patient with TG >400 mg/dL and then ask for the next step. The correct answer is to order a direct LDL-C measurement, not to apply the formula. Students who calculate LDL-C using Friedewald in this setting will get an inaccurate value and choose the wrong management.
Watch for vignettes presenting very high triglycerides (≥500 mg/dL) with epigastric pain. The primary concern is pancreatitis prevention, and the first-line drug is a fibrate, not a statin. However, if the question asks about long-term cardiovascular risk reduction in a patient with elevated TG and high cardiovascular risk, the answer shifts back to statin as first-line.
Remember that statin is contraindicated in pregnancy and breastfeeding. A question featuring a woman of reproductive age on statin therapy who is now planning pregnancy should prompt you to select discontinuation of statin 1-2 months before conception.
For the monitoring section, a frequently tested scenario is a patient on statin who develops myalgia with CK elevation. If CK is <4x ULN, continue therapy with monitoring. If CK is >10x ULN, stop statin immediately and evaluate for rhabdomyolysis (check renal function). Do not confuse routine CK monitoring (not recommended) with symptom-driven CK testing (only when the patient reports muscle complaints).
Finally, the distinction between Alur 1 and Alur 2 is itself testable in the Indonesian licensing exam context. Alur 1 (ATP III) is a target-driven model where each risk category has a defined LDL-C number to achieve. Alur 2 (ACC/AHA 2018) is an intensity-driven model that prioritizes statin potency classification (high vs. moderate vs. low intensity) and introduces the concept of add-on non-statin therapy (ezetimibe, then PCSK9 inhibitor) specifically for very high-risk patients who fail to reach LDL-C <70 mg/dL on maximally tolerated statin. When the exam presents a patient with ASCVD who remains at LDL-C 85 mg/dL on atorvastatin 80 mg, the next best step is to add ezetimibe, not to switch statins or increase the dose further.